RT Journal Article
SR Electronic
T1 Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.26.24309525
DO 10.1101/2024.06.26.24309525
A1 Lugano, Doreen
A1 Kutima, Bernadette
A1 Kimani, Makobu
A1 Sigilai, Antipa
A1 Gitonga, John
A1 Karani, Angela
A1 Akech, Donald
A1 Karia, Boniface
A1 Ziraba, Abdhalah K.
A1 Maina, Angela
A1 Lambisia, Arnold
A1 Omuoyo, Donwilliams
A1 Mugo, Daisy
A1 Lucinde, Ruth
A1 Newman, Joseph
A1 Bailey, Dalan
A1 Nduati, Eunice
A1 Githinji, George
A1 Agoti, Charles N.
A1 Bejon, Philip
A1 Scott, J Anthony G
A1 Agweyu, Ambrose
A1 Kagucia, Wangeci
A1 Warimwe, George M
A1 Sande, Charles
A1 Ochola-Oyier, Lynette I
A1 Nyagwange, James
YR 2024
UL http://medrxiv.org/content/early/2024/06/26/2024.06.26.24309525.abstract
AB Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and March 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Wellcome Trust (grants 226141/Z/22/Z, 226130/Z/22/Z, 227131/Z/23/Z & 227131/B/23/Z 226141/Z/22/Z and 226002/A/22/Z), MRC (MR/W005611/1, MR/Y004205/1), BBSRC (BBS/E/I/COV07001, BBS/E/I/00007031), and Bill and Melinda Gates Foundation (INV-039626).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kenya Medical Research Institute, Scientific Ethics Review Unit gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAdd data produced are available online at https://doi.org/10.7910/DVN/6DSHMB